Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity of California, San Francisco
About this trial
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
Eligibility criteria
Qualifiers
Active RR-TB diagnosed at a study facility during the study period
Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)
Disqualifiers
Patient expects to relocate/move residence outside of the study region
Patient does not agree to participate in the study
Trial design
Treatments tested in this trial
- Targeted next-generation sequencing
Treatment groups
2,500 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, San Francisco
Lead sponsor
University of Stellenbosch
Collaborator
National Health Laboratory Service (NHLS), South Africa
Collaborator
National Institute for Communicable Diseases, South Africa
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Find
Collaborator
Translational Genomics Research Institute
Collaborator
University Hospital Heidelberg
Collaborator
Source ClinicalTrials.gov